The diagnostic utility of genomic sequencing-exome and genome sequencing-has been documented in a variety of patient populations; but quantifying the clinical value, which is needed for widespread adoption, is more challenging. In this issue, Friedman et al. contemplate how the clinical value of genomic sequencing might be estimated in acutely ill infants in neonatal and pediatric intensive care units. The authors assert that investigations of clinical value must consider the effects of genomic sequencing that extend beyond simply making a diagnosis. They delineate the information they believe will be required and discuss the benefits and limitations of various measures including the ACCE (analytical validity, clinical validity, clinical utility, and associated ethical, legal, and social implications) framework, mortality, length of stay, and qualityand disability-adjusted life years (QALYs and DALYs), considering each in the context of current standards of care. The authors conclude that explorations of clinical value should frame genomic sequencing as a comprehensive scan for disease as opposed to a large panel of single-gene tests and suggest that genomic sequencing should be compared with chromosomal microarray, per case of serious disease diagnosed. In an associated comment also in this issue, Grosse and Farnaes discuss the recommendations of Friedman et al. and emphasize the importance of evaluating whether genomic sequencing explains patient phenotypes and whether test results impact patient management and outcomes. In comparison with standard of care, Grosse and Farnaes make a case for calculating the reduction in hospital days for nonfatal outcomes rather than assessing mortality. They also note that the perceived and actual value of a diagnosis and costs and benefits to relatives and families are also important metrics and argue that real-world observations may remain the main source of data, with compilation of information from multiple sites providing optimal data for analysis. 
